Skip to content

Gastro-enteritis admissions in hospitals: incidence and aetiology

Gastro-enteritis admissions in hospitals: incidence and aetiology - GEops: Gastro-enteritis admission surveillance

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON31820
Enrollment
1800
Registered
2008-01-15
Start date
2008-05-03
Completion date
Unknown
Last updated
2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastro-enteritis

Interventions

None listed

Sponsors

Ministerie van Volksgezondheid, Welzijn en Sport (VWS)
Lead Sponsor

Eligibility

Age
2 Years to 99 Years

Inclusion criteria

Inclusion criteria: A person with complaints of diarrhoea and or vomiting, who is being submitted to the hospital

Exclusion criteria

Exclusion criteria: Not having diarrhoea or vomiting complaints, having had diarrhoea or vomiting complaints in the two weeks before the current episode, being younger than 2 weeks

Design outcomes

Primary

MeasureTime frame
Incidence of gastroenteritis admissions. Incidence of the following pathogens in patients hospitalised because of gastroenteritis: Bacteriology (RT-PCR): Salmonella, Shigella, Campylobacter, Yersinia, shigatoxin producing E. coli (STEC), entero-aggregative E. coli (EAggEC), enteropathogenic E. coli (EPEC) and Clostridium difficile Virology (RT-PCR): rota-, adeno-, astro-, noro- and sapovirus Parasitology (microscopy and ELISA): Cryptosporidium, Giardia and Dientamoeba fragilis. The course of illness per pathogen in patients hospitalised because of gastroenteritis, including complications, chronic complaints and costs.

Secondary

MeasureTime frame
The DNA isolated from feces for detection of the pathogens will be used for determining genetic polymorphisms in these patients groups. This study will test genes involved in the specific immune response, in particular Th 1 genes, genes involved in innate immunity, and genes involved in inflammatory responses. The frequency of these polymorphisms will be compared to the frequencies determined in population controls in earlier studies. Furthermore, patients groups infected with different pathogens will be compared for frequencies of the polymorphisms.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)